EMPALINA is indicated for treating glycemic control levels in type 2 diabetes.

We took a striking visual treatment to relay the message that healthcare providers now have more ways to treat one indication.

“This one-pill combination combination targets two different physiologies of diabetes, both the insulin secretion and blood glucose aspect, and we believe this offers physicians an important solution to individulaize therapy of their type 2 patients.” - Christophe Arbet-Engels, MD, PhD, vice president, metabolic-clinical development and medical affairs

(Empa/Lina is known as empagliflozin/linagliptin)

Agency: Area 23

Role: Copy Supervisor